---
document_datetime: 2025-09-18 12:01:57
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/leqvio-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: leqvio-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.241854
conversion_datetime: 2025-12-28 17:37:15.035153
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Leqvio

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                               | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                 |
|----------------------|-------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------------------------------------------------------------------|
| EMA/R/0000247528     | Renewal of marketing authorisation. | 22/05/2025                          | 30/07/2025                                  | Annex II and PL                  | Based on the review of data on quality, safety, and efficacy, the CHMP considered that the benefit-risk |

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                            |                                                          |            |     |     | balance of Leqvio in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.   |
|----------------------------|----------------------------------------------------------|------------|-----|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUR / EMA/PSUR/0000257862 | Periodic Safety Update EU Single assessment - inclisiran | 10/07/2025 | n/a | n/a | PRAC recommendation - maintenance                                                                                                                               |